PMID- 38279333
OWN - NLM
STAT- MEDLINE
DCOM- 20240202
LR  - 20240202
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 25
IP  - 2
DP  - 2024 Jan 22
TI  - Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary 
      Biliary Cholangitis.
LID - 10.3390/ijms25021333 [doi]
LID - 1333
AB  - Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that 
      leads to the destruction of the intrahepatic bile ducts. While the inflammatory 
      process can be mediated by monocyte chemotactic protein-1 (MCP-1), the importance 
      of circulating MCP-1 as a biomarker is unclear. Our aim was to assess the 
      diagnostic significance of the serum concentrations of MCP-1 in PBC patients. We 
      compared circulating MCP-1 with biochemical, immunological and histological 
      parameters. Serum samples were collected from 120 PBC patients, 60 pathologic 
      controls and 30 healthy donors. MCP-1 levels were determined by using commercial 
      enzyme-linked immunosorbent assay (ELISA). Elevated serum MCP-1 levels were 
      detected in 66% of PBC patients with a specificity of 97%. Significantly higher 
      levels of MCP-1 protein were found in the sera of patients with PBC than in the 
      group of healthy individuals-410.2 pg/mL vs. 176.0 pg/mL, p < 0.01). Patients 
      with higher concentrations of alkaline phosphatase also had higher levels of 
      MCP-1 (r = 0.4, p < 0.01). In accordance with Ludwig's classification, a positive 
      correlation of serum MCP-1 concentration with the degree of fibrosis was 
      observed, OR = 6.1, p = 0.0003. We compared the MCP-1 with procollagen type III, 
      hyaluronic acid (HA), FIB-4 index, APRI and collagen type IV when predicting the 
      advance of liver fibrosis. Circulating MCP-1 is better correlated with liver 
      fibrosis and is also associated with the occurrence of specific antimitochondrial 
      autoantibodies and specific anti-nuclear autoantibodies-anti-gp210. MPC-1 can be 
      considered to be a tool for diagnosing the degree of fibrosis in PBC, and 
      combinations of MCP-1 and other specific biomarkers could support the diagnosis 
      of PBC.
FAU - Bauer, Alicja
AU  - Bauer A
AUID- ORCID: 0000-0003-2051-1177
AD  - Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical 
      Education, Marymoncka 99/103, 00-022 Warsaw, Poland.
FAU - Rawa, Tomasz
AU  - Rawa T
AD  - Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of 
      Postgraduate Medical Education, Roentgena 5, 02-781 Warsaw, Poland.
LA  - eng
GR  - 501-1-025-01-23/MG6/Centre of Postgraduate Medical Education/
GR  - 501-1-25-01-23/Centre of Postgraduate Medical Education/
PT  - Journal Article
DEP - 20240122
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Humans
MH  - Autoantibodies/blood
MH  - *Biomarkers/blood
MH  - *Chemokine CCL2/blood
MH  - Fibrosis
MH  - *Liver Cirrhosis, Biliary/blood/diagnosis
PMC - PMC10816849
OTO - NOTNLM
OT  - MCP-1
OT  - autoantibodies
OT  - liver fibrosis
OT  - primary biliary cholangitis
COIS- The authors declare no conflicts of interest.
EDAT- 2024/01/27 12:43
MHDA- 2024/01/29 06:43
PMCR- 2024/01/22
CRDT- 2024/01/27 01:01
PHST- 2023/12/15 00:00 [received]
PHST- 2024/01/17 00:00 [revised]
PHST- 2024/01/18 00:00 [accepted]
PHST- 2024/01/29 06:43 [medline]
PHST- 2024/01/27 12:43 [pubmed]
PHST- 2024/01/27 01:01 [entrez]
PHST- 2024/01/22 00:00 [pmc-release]
AID - ijms25021333 [pii]
AID - ijms-25-01333 [pii]
AID - 10.3390/ijms25021333 [doi]
PST - epublish
SO  - Int J Mol Sci. 2024 Jan 22;25(2):1333. doi: 10.3390/ijms25021333.